Rapalogs and inhibitors of CDK4/CDK6 ribociclib and palbociclib can improve response of ER+/HER2− breast cancer to hormone therapies, but how to best identify which patient benefits from one or the other therapy is unknown25. Here, CDK4 is linked to breast cancer.